GRAPPA Trainee Symposium 2020: A Summary of Oral and Poster Presentations.

Journal

The Journal of rheumatology
ISSN: 0315-162X
Titre abrégé: J Rheumatol
Pays: Canada
ID NLM: 7501984

Informations de publication

Date de publication:
01 Apr 2021
Historique:
entrez: 2 4 2021
pubmed: 3 4 2021
medline: 3 4 2021
Statut: aheadofprint

Résumé

The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) held a trainee symposium at its 2020 virtual meeting. Dermatology and rheumatology trainees presented their work on psoriasis and psoriatic arthritis. This report briefly reviews the 5 oral presentations and 25 posters presented at the event.

Identifiants

DOI: 10.3899/jrheum.201670 PMID: 33795328
pubmed: 33795328
pii: jrheum.201670
doi: 10.3899/jrheum.201670
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Christopher T Richlin (CT)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; A. Armstrong, MD, PhD, University of Southern California, Los Angeles, California, USA; H. Johnsson, MD University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; M.L. Mulder, MD, Resident of Rheumatology, Department of Rheumatology, Sint Maartenskliniek, and Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. AA has received research funding from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, Janssen Ortho Inc., Kyowa Hakko Kirin, Leo Pharma, Pfizer Inc., Sanofi Genzyme, UCB Pharma; and honorariums from AbbVie, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma. CTR, HJ, and MLM declare no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. C.T. Ritchlin, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA. Email: Christopher_Ritchlin@urmc.rochester.edu.
ORCID: 0000-0002-2602-1219

April Armstrong (A)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; A. Armstrong, MD, PhD, University of Southern California, Los Angeles, California, USA; H. Johnsson, MD University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; M.L. Mulder, MD, Resident of Rheumatology, Department of Rheumatology, Sint Maartenskliniek, and Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. AA has received research funding from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, Janssen Ortho Inc., Kyowa Hakko Kirin, Leo Pharma, Pfizer Inc., Sanofi Genzyme, UCB Pharma; and honorariums from AbbVie, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma. CTR, HJ, and MLM declare no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. C.T. Ritchlin, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA. Email: Christopher_Ritchlin@urmc.rochester.edu.
ORCID: 0000-0003-0064-8707

Hanna Johnsson (H)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; A. Armstrong, MD, PhD, University of Southern California, Los Angeles, California, USA; H. Johnsson, MD University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; M.L. Mulder, MD, Resident of Rheumatology, Department of Rheumatology, Sint Maartenskliniek, and Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. AA has received research funding from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, Janssen Ortho Inc., Kyowa Hakko Kirin, Leo Pharma, Pfizer Inc., Sanofi Genzyme, UCB Pharma; and honorariums from AbbVie, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma. CTR, HJ, and MLM declare no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. C.T. Ritchlin, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA. Email: Christopher_Ritchlin@urmc.rochester.edu.
ORCID: 0000-0003-1916-6222

Michelle L M Mulder (MLM)

As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. C.T. Ritchlin, MD, MPH, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; A. Armstrong, MD, PhD, University of Southern California, Los Angeles, California, USA; H. Johnsson, MD University of Glasgow, Institute of Infection, Immunity and Inflammation, Glasgow, UK; M.L. Mulder, MD, Resident of Rheumatology, Department of Rheumatology, Sint Maartenskliniek, and Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands. AA has received research funding from Boehringer Ingelheim/Parexel, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Galderma, Janssen Ortho Inc., Kyowa Hakko Kirin, Leo Pharma, Pfizer Inc., Sanofi Genzyme, UCB Pharma; and honorariums from AbbVie, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Leo Pharma, Modernizing Medicine, Novartis Pharmaceuticals Corp., Ortho Dermatologics, Pfizer Inc., Regeneron Pharmaceuticals, Sanofi Genzyme, and Sun Pharma. CTR, HJ, and MLM declare no conflicts of interest. This paper does not require institutional review board approval. Address correspondence to Dr. C.T. Ritchlin, Professor of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA. Email: Christopher_Ritchlin@urmc.rochester.edu.

Classifications MeSH